In8Bio, Inc.
INAB Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$0.96
KIRA · Stoqly’s AI analyst, in plain words
- In8Bio, Inc. lost $19.4M in fiscal 2025.
Market cap
$18.7M
P/E
—
Revenue
—
Net income
−$19.4M
Free cash flow
—
Operating margin
—
In8Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$19.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What In8Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- IN8BIO, INC.
- CIK
- 0001740279
In8Bio, Inc. · INAB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$14.7M | −$28.5M | −$30.0M | −$30.4M | −$19.4M |
| Diluted EPS | −$1.47 | −$1.36 | −$1.00 | −$17.05 | −$4.44 |
| Cash | |||||
| Cash from operations | −$13.5M | −$24.1M | −$23.3M | −$24.1M | −$12.7M |
| Share count change | 191.6% | 110.3% | 42.4% | −94.0% | 145.1% |
| Debt and strength | |||||
| Cash and short-term investments | $37.3M | $18.4M | $21.5M | $11.4M | $27.3M |
| Shareholders' equity | −$38.2M | $22.7M | $24.9M | $14.5M | $27.6M |
| Current ratio | 17.3x | 3.8x | 4.6x | 4.1x | 8.8x |
| Returns and quality | |||||
| Return on equity | — | — | −125.9% | −154.4% | −92.5% |
| Return on tangible equity | — | −125.5% | −120.3% | −210.2% | −70.5% |
| Altman Z'' | −9.1 | −6.3 | −8.1 | −23.4 | −7.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In8Bio, Inc. · INAB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.96 a share, the company is worth $18.7M.
Source: SEC EDGAR XBRL filings (CIK 0001740279). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.